Commission Members

Dr. Fiellin is Professor of Internal Medicine, Emergency Medicine, and Public Health (Health Policy and Management) at the Yale Schools of Medicine and Public Health, in New Haven, CT. He is the inaugural Director of the Yale Program in Addiction Medicine. Fiellin has focused his scholarly work on the interface between primary care, general healthcare settings, and addiction. He conducts research on the transfer of treatments for opioid use disorder and alcohol use disorder from specialized settings to office-based, primary care, Emergency Department and HIV specialty settings. He has conducted research on methadone medical maintenance and oversaw buprenorphine education for ASAM for five years. Dr. Fiellin was the recipient of AATOD’s Nyswander/Dole award in 2006 and represented the College on Problems of Drug Dependence (CPDD) as Co-Chair of the 2014 American Pain Society/CPDD/Heart Rhythm Society methadone safety guideline. He was Chair of the NIDA CTN Methadone Research Task Force and is the lead investigator of CTN 0131 investigating pharmacy-dispensed buprenorphine versus methadone using a DEA exception process.

Dr. Burnett is an Assistant Professor in Addiction Medicine at the University of Maryland Midtown Campus, a consultant for the Maryland Addiction Consultation Service and medical director of several community opioid treatment programs across the state of Maryland. Additionally, he serves as a Vice Chair of the American Society of Addiction Medicine (ASAM) Legislative and Public Policy Committee. He previously served as the Medical Director for the Center for Harm Reduction Services for the Maryland Department of Health, where he oversaw the statewide naloxone distribution and syringe service programs. Broadly, Dr. Burnett's work aims to advance drug policy reform with the goal of shifting United States drug policy from a framework based on criminal justice to one based on public health.

Ms. Curry is an accomplished compliance and drug policy expert with over 43 years of experience in federal regulatory enforcement. She is a former Diversion Investigator with the Drug Enforcement Administration (DEA), serving in both field and headquarters positions. During her tenure with the DEA, Ms. Curry facilitated the successful negotiation of a national voluntary restriction on retail sales of methadone, contributing to notable reductions in unintentional overdose mortalities. She is the Founder and President of Pharma Advisory Group LLC (PAG), a consulting firm that provides strategic guidance on compliance with federal Controlled Substance Act (CSA) laws and regulations.

Professor Dooling is an Assistant Professor at Moritz College of Law, The Ohio State University, in Columbus, OH. She studies and teaches federal administrative law, regulatory policy, and statutory interpretation. She is co-chair of the annual administrative law conference hosted by the American Bar Association’s Section of Administrative Law and Regulatory Practice, member of the executive committee of the Administrative Law Section of the Association of American Law Schools (AALS), and a Senior Fellow at the Administrative Conference of the United States (ACUS). For over 10 years, Professor Dooling served as a deputy branch chief, senior policy analyst, and attorney for the Office of Information and Regulatory Affairs (OIRA) at the U.S. Office of Management and Budget (OMB), where she reviewed draft regulations from a number of federal agencies, including the Food & Drug Administration (FDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Centers for Medicare & Medicaid Services (CMS), among others. Her co-authored research on methadone—published in the Annals of Health Law, Lancet Public Health, and Health Affairs Scholar, among other journals—includes legal analysis informing the extension of pandemic flexibilities for OUD treatment beyond the pandemic, the range of federal regulatory barriers to methadone treatment and how they could be changed without legislative action, and analysis of studies measuring the consequences of pandemic flexibilities. Professor Dooling also served as a member of the Planning Committee for the Workshop on Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws hosted by the National Academies of Sciences, Engineering, and Medicine (NASEM).

Dr. Hill is Associate Professor of Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy in Pittsburgh, PA. He serves as Executive Director of the Implementation and Research Center for Healthy Communities (IRC) which seeks to improve health and well-being through innovative health services research, robust curriculum development and evaluation, and application of implementation science principles to advance evidence-based practices in healthcare and community settings. Dr. Hill's current research focuses on identifying, exploring, and addressing gaps in pharmacy implementation of evidence-based substance use disorder treatment and harm reduction strategies. He is also principal investigator for the Pennsylvania Opioid Use Disorder Centers of Excellence Care Management Technical Assistance Project. Dr. Hill serves on the board of directors of the Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) and on the editorial board of the Journal of the American College of Clinical Pharmacy (JACCP).

Dr. Hodgkin is a Professor at the Heller School for Social Policy and Management, at Brandeis University. He is also a co-investigator at the Brandeis-Harvard SPIRE Center (Systems Performance Improvement Research and Engagement) and conducts his research at the Heller School’s Schneider Institute for Behavioral Health. Dr. Hodgkin is a health economist with over 30 years of experience in health policy analysis and research in academic settings. Most of his research focuses on the effects of different organizing and financing approaches in health care, particularly for mental and substance use disorders. Dr. Hodgkin’s recent projects include a review of payment-related barriers to medications for opioid use disorder; work on the sustainability of different novel delivery models for treating substance use and mental disorders; and a study of the use of patient incentives and care navigators to connect Medicaid patients in Massachusetts detoxification programs to specialty substance use disorder treatment.

Dr. Jordan is the Barbara Wilson Endowed Professor of Psychiatry and Professor of Population Health at New York University's Grossman School of Medicine. As Principal Investigator (PI) for the Jordan Wellness Collaborative, Dr. Jordan leads a research, education, and clinical program that partners with community members to provide optimal access to people with mental health and substance use disorders. Through her multifaceted work, she provides addiction treatment in faith settings, studies health outcomes for people with opioid use disorder in the carceral system, and trains addiction specialists to provide culturally informed treatment.

Building on this portfolio, Dr. Jordan leads several NIH and privately funded studies focused on reducing substance use related health disparities through community based, harm reduction approaches. Her NIDA-funded study, Addressing Health Disparities by Providing Evidence Based Treatment in the Black Church, examines outcomes among Black adults with alcohol use disorder receiving care in church-based settings compared to specialty addiction treatment. She also serves as Multiple Principal Investigator on the NIH-funded Imani Breakthrough Project, a faith-based, person-centered recovery program implemented in churches that integrates medication for addiction treatment in communities experiencing high overdose burden. In addition, Dr. Jordan leads a NIDA-funded study, Integrated Harm Reduction Services for People Who Use Drugs in Targeted Areas of High Overdose Rates, which focuses on evaluating initiation and engagement of adults in services as usual at two mobile community harm reduction organizations compared to harm reduction services as usual coupled with linkages to social determinants of health services.

Ms. Kennedy is a Certified Recovery Peer Advocate. In her work as a Peer Engagement Specialist at Mount Sinai Beth Israel in New York, NY, she conducts street outreach and presents at area meetings to educate community members about substance use disorders and available resources and deliver trainings in naloxone administration. She is the current President of the National Alliance for Medication Assisted Recovery (NAMA-R), serves as the Peer Representative for the Manhattan Council on Treatment, Harm Reduction, Addiction, Recovery, and Prevention, and has been selected to join the New York State OASAS Credentialing Board as a Peer Representative. She is winner of the NAMA-R 2024 Richard Lane/Robert Holden Patient Advocacy Award. Through her work, Kennedy endeavors to make medication-based treatments available to all.

Dr. Lofwall is Professor of Psychiatry and Behavioral Science, and Bell Alcohol and Addictions Endowed Chair, at the University of Kentucky College of Medicine in Lexington, KY. She is board-certified in psychiatry and addiction medicine. She currently serves as medical director of the University of Kentucky's Robert Straus and First Bridge Clinics, which provide comprehensive opioid use disorder treatment within the University of Kentucky Center on Drug and Alcohol Research. She oversees the Bell Addiction Medicine Scholar Program. Her work centers around improving the care of patients with addiction, and her research has included evaluation of novel treatments for opioid use disorder (OUD), understanding factors associated with diversion, improving care of complex patients with OUD and infections, and best practices for linking and retaining persons in care for OUD treatment. She was elected as a Distinguished Fellow of American Society of Addiction Medicine (ASAM) and the American Psychiatric Association, is a past President of the Kentucky Chapter of ASAM, a former ASAM board member. She has received numerous teaching and mentoring awards and was an expert panel member for SAMHSA’s Treatment Improvement Protocol on Medication Treatment for Opioid Use Disorder and invited speaker to the National Academy of Medicine.

Dr. McCarty is Professor in the Department of Public Health & Preventive Medicine at Oregon Health & Science University, in Portland, OR. He works at the intersection of policy, research and practice assessing the organization, financing, and quality of prevention and treatment services for alcohol and substance use disorders. Dr. McCarty served as the Director of the Education Core for the Methamphetamine Abuse Research Center, the co-Principal Investigator (PI) for the Western States Node of the National Drug Abuse Treatment Clinical Trials Network, and the PI for an evaluation of the impacts of Oregon’s Coordinated Care Organizations on prevention and treatment for alcohol and substance use disorders. He was the Academic Director for the University of Amsterdam’s Summer Institute on Alcohol, Drugs and Addiction. Between 1989 and 1995, Dr. McCarty directed the Massachusetts Bureau of Substance Abuse Services for the Massachusetts Department of Public Health. He also served on the Oregon Alcohol and Drug Policy Commission and the Governor’s Task Force on Prescription Drug Misuse and Abuse.

Dr. Meyerson is the Beverly Benson McCord Endowed Chair of Nursing, a Professor of Nursing and of Family and Community Medicine, and the Policy Director for the Comprehensive Center for Pain and Addiction at the University of Arizona. Dr. Meyerson also directs the Harm Reduction Research Lab with a national, transdisciplinary faculty from 9 universities. Meyerson’s research is focused on the reduction of opioid overdose death and bloodborne illness and infection through policy and practice innovations in medicine, pharmacy and nursing. As the Beverly Benson McCord Endowed Chair in Nursing, Dr. Meyerson also seeks to understand the unique needs of aging populations at the intersection of pain and opioid use disorder to improve patient screening, diagnosis and treatment. As experts in implementation science and community-based participatory action research (CBPAR), Meyerson and her team partner with people who have lived/living drug use experience, with opioid use disorder treatment providers, funders, and regulators through the Drug Policy Research and Advocacy Board.

Dr. Sherrick is an internist board-certified in addiction medicine, who has been providing medication-based treatments for opioid use disorder since 2003. He is Chief Science Officer for Community Medical Services, a company that serves patients through over 70 Opioid Treatment Programs (OTPs) in 12 states. Prior to joining CMS, first as Chief Medical Officer and subsequently in his current role, Sherrick treated patients with substance use disorder and dual psychiatric diagnoses at Pathways Treatment Center in Kalispell, MT. He has established a state-wide buprenorphine treatment program for VA Montana with extensive use of telemedicine and is past President of the Northwest Chapter of the American Society of Addiction Medicine.

Dr. Stoller is a Professor of Clinical Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine. He is Director and Medical Director of the Johns Hopkins Broadway Center for Addiction, the hospital’s outpatient addiction treatment program. He also serves as an inpatient psychiatrist on a dual diagnosis unit, and as Medical Director, Behavioral Health at Johns Hopkins Health Plans, which administers four health insurance plans. His area of clinical expertise is the treatment of substance use problems and, in particular, the use of methadone and buprenorphine in the treatment of opioid use disorder (OUD), with focus on structuring treatment to maximize quality while improving access, driving engagement through provision of valued and patient-centered care, reducing barriers to engagement, and fostering sensible policy and reimbursement models.

Dr. Stoller’s research interests have centered on cost issues as they relate to drug use and treatment; methods to enhance treatment engagement and retention; and co-occurring psychiatric, medical, pain, and substance use disorders. His published manuscripts and book chapters focus on the use of adaptive stepped care, treatment incentives, and integrated treatment of co-occurring disorders. He also served as the prescribing physician for an early pilot study of methadone pharmacy prescribing for OUD (pub 2022).

Accelerated by his service on the Board of Directors of the American Association for the Treatment of Opioid Dependence (AATOD) and its Maryland state chapter, Dr. Stoller has increasingly focused his attention on increasing access to, and quality of, addiction therapies in Baltimore, the region, and nationally. He has also served in formal advisory roles for HHS/SAMHSA, The Joint Commission (TJC), National Academy of Medicine (NAM), the State of Maryland, Baltimore City and provider associations such as the APA and AAAP/PCSS. Dr. Stoller created and implemented the first known buprenorphine hub and spoke collaborative care model in the nation (“CoOP”, 2009), still operating today.

Mr. Talbott is a Licensed Alcohol and Drug Abuse Counselor (LADAC), Tennessee Qualitied Clinical Supervisor (QCS), licensed social worker, and President of Talbott Legacy Centers located in Maryville, TN. He is a nationally recognized expert in comprehensive opioid use disorder treatment, and prior to opening TLC, founded and operated outpatient opioid treatment programs (OTPs) in Georgia and North Carolina. As an individual in recovery with lived experience of opioid use disorder, Talbott grounds his work in the understanding that "one size doesn't fit all" and approaches to substance use and addiction treatment must be evidence-based and patient-centered. He is a long-time Recovery Month Planning Partner with SAMHSA and previously served on the Board of Directors for the National Alliance for Medication Assisted Recovery (NAMA-R). Talbott is the 2019 recipient of the Richard Lane & Robert Holden MAT Advocacy Award from the American Association for the Treatment of Opioid Dependence (AATOD), a prestigious national award given to one individual in the United States every 18 months for exemplary achievements in MAT advocacy and influencing related policy, and the 2021 recipient of the Lisa Mojer-Torres Award from Faces & Voices of Recovery.